 | Better health in Africa: Experience and lessons learned (WB, 1994, 260 p.) | |
| Comparative analysis of national drug policies: Second workshop, Geneva, 10-13 June 1996 (WHO/DAP, 1997, 175 p.) | |
| Counterfeit drugs (WHO/EDM, 1999, 61 p.) | |
| Criteria for medicinal drug promotion (WHO, 1988, 8 p.) | |
| Drug quality control laboratories (WHO/AFRO, 1999, 41 p.) | |
| First-year experiences with the Interagency Guidelines for Drug Donations (WHO/EDM, 2000, 51 p.) | |
| General guidelines for methodologies on research and evaluation of traditional medicine (WHO/EDM, 2000, 80 p.) | |
| General principles for guidance in devising International Nonproprietary Names for pharmaceutical substances (WHO/EDM, 25 p.) | |
| Globalization and access to drugs (WHO/EDM, 1999, 97 p.) | |
| Guide to good prescribing: A practical manual (WHO/EDM, 1994, 115 p.) | |
| Guidelines for drug donations: Revised 1999 (Caritas - WCC - ICRC - IFRC - FIP - UNAIDS - MSF - UNHCR - Oxfam - PSF - UNICEF - UNDP - UNFPA - WB - WHO/EDM, 1999, 24 p.) | |
| Guidelines for good clinical practice (GCP) for trials on pharmaceutical products (WHO Technical Report Series, No. 850, 1995, Annex 3) (WHO, 1995, 36 p.) | |
| Guidelines for safe disposal of unwanted pharmaceuticals in and after emergencies (WCC - ECHO - ICRC - IFRC - FIP - ISWA - MSF - UNHCR - Oxfam - PSF - UNICEF - UNDP - WHO/EDM, 1999, 36 p.) | |
| Guidelines for the WHO Review of Dependence-Producing Psychoactive Substances for International Control (WHO/EDM, 2000, 22 p.) | |
| Guidelines on basic training and safety in acupuncture (WHO/EDM, 1999, 35 p.) | |
| Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances (WHO/DMP, 1997, 41 p.) | |
| Index of pharmacopoeias (WHO/EDM, 2001, 10 p.) | |
| Indicators for monitoring national drug policies (WHO/EDM, 1999, 250 p.) | |
| Injection practices in the developing world: A comparative review of field studies in Uganda and Indonesia (WHO/DAP, 1996, 149 p.) | |
| International strategies for tropical disease treatments: Experiences with praziquantel (WHO/DAP, 1998, 113 p.) | |
| Joint bulk purchasing of essential drugs - Achats groupés de médicaments essentiels (A.C.A.M.E. - WHO/AFRO, 1999, 28 p.) | |
| Medicinal plants: An expanding role in development (WB, 1996, 32 p.) | |
| Medicinal plants in Viet Nam (Institute of Materia Medica - HANOI - WHO/WPRO, 1990, 444 p.) | |
| Medicinal plants: Rescuing a global heritage (WB, 1997, 80 p.) | |
| Model guidelines for the international provision of controlled medicines for emergency medical care (WHO/PSA, 1996, 14 p.) | |
| Narcotic and psychotropic drugs: Achieving balance in national opioids control: Guidelines for assessment (WHO/EDM, 2000, 41 p.) | |
| The new emergency health kit 98: Drugs and medical supplies for 10,000 people for approximately 3 months (COE - ICRC - IDA - IFRC - MSF - Oxfam - UNICEF - UNFPA - WHO/DAP, 1998, 82 p.) | |
| Operational principles for good pharmaceutical procurement (UNICEF - UNFPA - WB - WHO/EDM, 1999, 32 p.) | |
| Patent situation of HIV/AIDS-related drugs in 80 countries (UNAIDS - WHO/EDM, 2000, 11 p.) | |
| Pharmaceuticals and the WTO TRIPS Agreement: Questions and answers (UNAIDS - WHO/EDM, 2000, 5 p.) | |
| Procedure for the selection of Recommended International Nonproprietary Names for pharmaceutical substances (WHO/EDM, 3 p.) | |
| Producing national drug and therapeutic information: The Malawi approach to developing standard treatment guidelines (WHO/DAP, 1994, 49 p.) | |
| Public education in rational drug use: A global survey (WHO/DAP, 1997, 97 p.) | |
| Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use (WHO/DAP, 1997, 115 p.) | |
| Reference substances and infrared reference spectra for pharmacopoeial analysis (WHO/EDM, 1999, 117 p.) | |
| Regulatory situation of herbal medicines: A worldwide review (WHO/TRM, 1998, 49 p.) | |
| The role of the pharmacist in self-care and self-medication (WHO/EDM, 1998, 17 p.) | |
| Selected topics in health reform and drug financing (WHO/DAP, 1998, 49 p.) | |
| Starting materials for pharmaceutical products: Control and safe trade (WHO/DMP, 1998, 10 p.) | |
| Study of the implications of the WTO TRIPS Agreement fotr the pharmaceutical industry in Thailand (The Centre for Health Economics, Faculty of Economics, Chulalongkorn University Bangkok - WHO Collaborating Centre for Health Economics - WHO/SEARO, 1999, 113 p.) | |
| The TRIPS Agreement and pharmaceuticals (Directorate General of Drug and Food Control - Indonesia - WHO, 2000, 91 p.) | |
| The use of essential drugs: Eight report of the WHO Expert Committee (WHO, 1998, 84 p.) | |
| Use of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (WHO/DAP, 1995, 156 p.) | |
| WHO Medicines Strategy: Framework for action in essential drugs and medicines policy 2000-2003 (WHO/EDM - WHO/AFRO - WHO/EURO - WHO/SEARO - WHO/AMRO - WHO/EMRO - WHO/WPRO, 2000, 81 p.) |